• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 billion

by October 23, 2024
written by October 23, 2024

(Reuters) – Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday.

As part of the deal, the U.S. drugmaker paid $30 million upfront. Modifi is also eligible to receive potential milestone payments of up to $1.3 billion in exchange for a new class of therapies, KL-50 — being developed against difficult-to-treat brain tumors, including glioblastomas.

New Haven, Connecticut-based Modifi is a pre-clinical stage company, which develops cancer therapies that aim to selectively kill cancer cells by modifying cancer DNA.

Modifi has raised $10.7 million to date in seed funding and is backed by investors including American Cancer Society’s investment arm, BrightEdge.

Merck has been in pursuit of eligible candidates that could potentially make up for a loss of revenue from its aging blockbuster cancer immunotherapy, Keytruda, which is set to lose its patent protection by the end of the decade.

Last year, the company struck a $5.5 billion deal with Japan’s Daiichi Sankyo to jointly develop three of its targeted cancer therapies, known as antibody drug conjugates, which work like “guided missiles” against tumor cells while sparing healthy ones.

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
Earnings call: Cadence Bank reports steady Q3 growth, eyes future momentum
next post
Buy recent pullback in Microsoft shares: Citi

You may also like

BASF results down on impairments, restructuring

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Lawyer group urges overhaul of US bank charter...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Procter & Gamble to cut 7,000 jobs as part of broader restructuring

      June 6, 2025
    • Shein and Temu see U.S. demand plunge as loophole for cheap goods closes

      June 6, 2025
    • Shein and Temu see U.S. demand plunge as loophole for cheap goods closes

      June 5, 2025
    • This California startup is cleaning water and removing CO₂ from the atmosphere — all at a reduced cost

      June 5, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (504)
    • Stock (6,426)

    Latest News

    • Procter & Gamble to cut 7,000 jobs as part of broader restructuring
    • Shein and Temu see U.S. demand plunge as loophole for cheap goods closes

    Popular News

    • Cytokinetics stock rises on Sanofi’s rights acquisition
    • Starboard Value CEO says Pfizer’s board should hold management accountable

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy